Abstract: This invention relates to a bacterial expression system for production of protective antigen (PA) against bacillus anthracis. Recombinant asporogenic B. anthracits that are derived from &Dgr;Sterne-1(pPA102) and show inability to bind the dye when grown on Congo Red Agar can be screened and asporogenic strains isolated using methods of the invention. organisms of the invention lacking spore-forming function may be killed by heat shock at temperatures as low as 60° C. for 60 minutes. Hence, contamination of the environment with viable spore-forming organisms is easily avoided and decontamination is easily accomplished.

Abstract: A processor apparatus is disclosed, for conditioning a portable cassette as part of a process in which biological cells contained within a sterilizable cell growth chamber of the cassette are maintained and grown ex vivo, without exposing the cells to the external environment. The processor apparatus includes a support configured to removably receive the portable cassette and to be movable in a controlled manner, and it further includes a flow control actuator engageable with a media flow path of the portable cassette, which communicates with the cell growth chamber.

Abstract: An incubator apparatus is disclosed, for conditioning a portable cassette such that biological cells contained within a cell growth chamber of the cassette are maintained and grown ex vivo, without exposing the cells to the external environment. The incubator apparatus includes first and second receptacles sized and configured to removably receive first and second casings, respectively, of the portable cassette, and it further includes first and second temperature regulators that regulate the temperatures of the respective first and second receptacles to prescribed values. In addition, the incubator apparatus includes a mechanical interface that is engaged by the portable cassette's first and second casings when they are received in their corresponding receptacles, and this mechanical interface controls the transport of growth media and a gas through the cassette's cell growth chamber, without exposing the cell growth chamber to the external environment.

Abstract: The present disclosure relates to Moraxella catarrhalis outer membrane vesicle (OMV) compositions, to selected antigenic proteins from the outer membranes of M. catarrhalis which have a variety of useful properties, and to monoclonal antibodies against these proteins. Particular "Outer Membrane Proteins" (OMPs) of the invention are characterized as having molecular weights of about 30 kD, 80 kD (also termed CopB protein) and between about 200 and 700 kD (HMWP antigen). Passive immunization with monoclonal antibodies directed against these proteins confers protection against homologous and heterologous Moraxella catarrhalis strains in animal models, and active immunization with outer membrane vesicles also enhances pulmonary clearance of distinct M. catarrhalis strains. This demonstrates both the utility of antibodies in conferring passive immunity and the usefulness of OMPs, or variants thereof, in the preparation of vaccines.

Abstract: High molecular weight surface proteins of non-typeable Haemophilus influenzae which exhibit immunogenic properties and genes encoding the same are described. Specifically, genes coding for two immunodominant high molecular weight proteins, HMW1 and HMW2, have been cloned, expressed and sequenced, while genes coding for high molecular proteins HMW3 and HMW4 have also been cloned, expressed and sequenced.

Abstract: A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.

Abstract: A protein from H. influenzae designated NucA is isolated and purified. The NucA protein has the amino acid sequence of amino acids 26-603 of SEQ ID NO:2 or a biologically equivalent amino acid sequence thereof. Amino acids 1-25 of SEQ ID NO:2 are the signal peptide, which is cleaved during processing of the mature protein. The NucA protein has a molecular weight of approximately 63,000 Daltons as measured on a 12% SDS-PAGE gel and possesses 5'-nucleotidase activity. The NucA protein is obtained by isolation and purification from the H. influenzae organism, by chemical synthesis or by recombinant expression by an isolated and purified nucA DNA sequence which encodes the NucA protein. Such a DNA sequence hybridizes under standard high stringency Southern hybridization conditions with a DNA sequence encoding the NucA protein of H. influenzae having the amino acid sequence of amino acids 26-603 of SEQ ID NO:2 or a biologically equivalent amino acid sequence thereof.

Abstract: A dual carrier immunogenic construct comprised of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least one secondary carrier comprising a T-dependent antigen conjugated to a primary carrier. The dual carrier immunogenic construct may further comprise moieties such as haptens and antigens. Such immunogenic constructs are suitable for use in the diagnosis, treatment, and prevention of diseases.

Abstract: Novel compositions are disclosed for use in the treatment or diagnosis of bovine pasteurellosis, commonly referred to as Shipping Fever. Cell-free Pasteurella haemolytica supernatants are employed to provide individual antigen compositions, identified through reaction with sera from naturally-infected or convalescent cattle. In particular, at least seven individual P. haemolytica antigen groups were recognized in cell-free culture supernatants. Purified P. haemolytica supernatant, formulated in a suitable pharmaceutical vaccine composition is shown to elicit a specific immune response, in both cows and rabbits, directed against the individual immunoreactive P. haemolytica polypeptides identified. Also disclosed are novel recombinant cells, plasmids and bacteriophage which include transcriptionally active P. haemolytica antigen genes. Recombinant clones are similarly selected to be reactive with naturally-infected antisera.

Abstract: Methods for the in vitro cultivation, propagation, and production of antigens of Ehrlichia phagocytophila genogroup granulocytic Ehrlichiae, including Ehrlichia equi, in Ixodes scapularis tick cell culture and in human HL60 promyelocytic leukemia cell culture.

Abstract: Compounds and methods are provided for diagnosing Trypanosoma cruzi infection. The disclosed compounds are polypeptides, or antibodies thereto, that contain one or more epitopes of T. cruzi antigens. The compounds are useful in a variety of immunoassays for detecting T. cruzi infection. The polypeptide compounds are further useful in vaccines and pharmaceutical compositions for inducing protective immunity against Chagas' disease in individuals exposed to T. cruzi.

Abstract: The invention provides compositions comprising an oligosaccharide of S. pneumoniae serotype 8 useful for stimulating an immune response to an antigen, methods of providing protective immunization against a bacterial pathogen using these compositions, methods of augmenting an immunogenic response to an antigen by administering these S. pneumoniae serotype 8 oligosaccharide compositions along with the antigen, and methods of making the immunostimulatory compositions described above.

Abstract: The present invention discloses a method for etching a silicon surface or forming alignment marks in a silicon substrate by first coating the substrate with an oxide layer, then depositing and patterning a photoresist layer on top of the oxide layer and forming the alignment marks by a dry etching process utilizing fluorine/oxygen etchant chemistry for the simultaneous etching of the two layers in a single process wherein the oxide layer prevents the contamination of the silicon wafer by any silicon particles formed.

Abstract: A substrate processing apparatus does not allow sudden boiling of supplementary liquid but rather sufficiently diffuses the supplementary liquid into processing liquid so that the temperature of the processing liquid does not decrease largely. De-ionized water (PW) is ejected through a plurality of de-ionized water blow-off openings (Ha) which are formed in a de-ionized water injection nozzle (10a). Inside an internal bath (1), which is located immediately below the de-ionized water blow-off openings, and close to a overflow part (20a) which is a top edge of a side surface (1a) of the internal bath (1), the de-ionized water reaches the surface of a phosphoric acid solution (PA). The de-ionized water thereafter reaches a gutter part (30a) of an external bath (2), as it is mixed with the phosphoric acid solution (PA), and flows into a reservoir part (30d) of the external bath (2).

Abstract: Disclosed are methods of purifying shiga-like toxins (SLTs) from Polymyxin B sulfate extracts of Verotoxin-producing Escherichia coli. The methods are facile, efficient and reproducible. In another aspect, the toxin is inactivated for use in a vaccine against SLT mediated disease conditions.

Abstract: This invention relates to a device comprising a hydrophobic solid support coated with a chemical that can capture bacterial lipopolysaccharides (LPS). This invention also relates to the use of such a device in an immunoassay for the detection of microorganisms. This invention also relates to the incorporation of such a device into a diagnostic kit.

Abstract: A vaccine for immunizing animals against diseases caused by microorganisms producing an osteolytic toxin is disclosed. The vaccine contains a Pasteurella multocida toxin or derivative thereof that has been rendered non-toxic by genetic and/or biochemical means. The toxin or derivative is encoded by a nucleotide sequence from Pasteurella multocida toxin which is inserted in an expression vector capable of replicating ina suitable host microorganism in which the sequence may be expressed.

Abstract: Antigenic and/or immunoregulatry material derived from Mycobacterium vaccae is useful in the treatment of mental diseases associated with an autoimmune reaction initiated by an infection and/or the auto immunologically mediated consequences (other than uveitis) of chronic infection.

Abstract: The present invention relates to water-in-oil and water-in-oil-in-water multiple emulsions and methods of preparation which overcome many of the limitations of previous emulsions and are superior preparations for use in numerous applications including, but not limited to, vaccine adjuvants, pharmaceuticals, cosmetics, foods, and various household and industrial uses.

Abstract: The present invention relates, in general, to a method for the high level expression of the outer membrane protein meningococcal group B porin proteins and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein meningococcal group B porin proteins in E. coli wherein the meningococcal group B porin proteins and fusion proteins thereof comprise more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of the meningococcal group B porin proteins and fusion proteins thereof and to their use in vaccines.